{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:33:13Z","timestamp":1790281993548,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe","doi-asserted-by":"publisher","award":["Micafungin IDS"],"award-info":[{"award-number":["Micafungin IDS"]}],"id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe","doi-asserted-by":"publisher","award":["Micafungin IDS"],"award-info":[{"award-number":["Micafungin IDS"]}],"id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We investigated covariates of pharmacokinetics of micafungin in critically ill patients. After application of micafungin, plasma samples were collected. Non-linear mixed effects modelling (NONMEM 7.3) was used to develop the pharmacokinetic model. Using this model, the adequacy of a fixed 100\u2009mg dosing regimen was evaluated in the study cohort. A two-compartment model with linear elimination was found to describe the obtained data. SOFA score was identified as a significant covariate on both clearance and central volume of distribution, respectively. Patients in highly critical condition, represented by a SOFA above 10 showed a 30.8% lower central volume of distribution than the less critically ill patients. For patients with bilirubin levels above 4\u2009mg\/dl, clearance was decreased by 21.1%. Renal replacement therapy (RRT) did not influence micafungin clearance or the volumes of distribution. In a posthoc evaluation of the modeled population, 100\u2009mg micafungin was suitable when assessing the PKPD targets (AUC\/MIC) for\n                    <jats:italic>C<\/jats:italic>\n                    .\n                    <jats:italic>albicans<\/jats:italic>\n                    and\n                    <jats:italic>C<\/jats:italic>\n                    .\n                    <jats:italic>glabrata<\/jats:italic>\n                    , with insufficient target attainment for\n                    <jats:italic>C<\/jats:italic>\n                    .\n                    <jats:italic>parapsilosis<\/jats:italic>\n                    . Micafungin pharmacokinetics appear not to be influenced by the status of RRT. A dose of 100\u2009mg micafungin is suitable for infections with\n                    <jats:italic>C<\/jats:italic>\n                    .\n                    <jats:italic>albicans<\/jats:italic>\n                    and\n                    <jats:italic>C<\/jats:italic>\n                    .\n                    <jats:italic>glabrata<\/jats:italic>\n                    in critically ill patients.\n                  <\/jats:p>","DOI":"10.1038\/s41598-019-53093-6","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T06:03:08Z","timestamp":1574920988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacokinetics of Micafungin in Critically Ill Patients"],"prefix":"10.1038","volume":"9","author":[{"given":"Silke","family":"Gastine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lanckohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Blessou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Fobker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Hempel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Ellger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"key":"53093_CR1","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1007\/s00134-016-4504-3","volume":"42","author":"SepNet-Critical-Care-Trials-Group","year":"2016","unstructured":"SepNet-Critical-Care-Trials-Group. Incidence of severe sepsis and septic shock in German intensive care units: the prospective, multicentre INSEP study. Intensive Care Med 42, 1980\u20131989, https:\/\/doi.org\/10.1007\/s00134-016-4504-3 (2016).","journal-title":"Intensive Care Med"},{"key":"53093_CR2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s00134-006-0517-7","volume":"33","author":"C Engel","year":"2007","unstructured":"Engel, C. et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 33, 606\u2013618, https:\/\/doi.org\/10.1007\/s00134-006-0517-7 (2007).","journal-title":"Intensive Care Med"},{"key":"53093_CR3","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00134-015-3866-2","volume":"41","author":"M Bassetti","year":"2015","unstructured":"Bassetti, M. et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med 41, 1601\u20131610, https:\/\/doi.org\/10.1007\/s00134-015-3866-2 (2015).","journal-title":"Intensive Care Med"},{"key":"53093_CR4","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00134-017-4731-2","volume":"43","author":"M Bassetti","year":"2017","unstructured":"Bassetti, M. et al. Intensive care medicine research agenda on invasive fungal infection in critically ill patients. Intensive Care Med 43, 1225\u20131238, https:\/\/doi.org\/10.1007\/s00134-017-4731-2 (2017).","journal-title":"Intensive Care Med"},{"key":"53093_CR5","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMra1315399","volume":"373","author":"BJ Kullberg","year":"2015","unstructured":"Kullberg, B. J. & Arendrup, M. C. Invasive Candidiasis. N Engl J Med 373, 1445\u20131456, https:\/\/doi.org\/10.1056\/NEJMra1315399 (2015).","journal-title":"N Engl J Med"},{"issue":"Suppl 7","key":"53093_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12039","volume":"18","author":"OA Cornely","year":"2012","unstructured":"Cornely, O. A. et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7), 19\u201337, https:\/\/doi.org\/10.1111\/1469-0691.12039 (2012).","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 7","key":"53093_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/1469-0691.12038","volume":"18","author":"M Cuenca-Estrella","year":"2012","unstructured":"Cuenca-Estrella, M. et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 18(Suppl 7), 9\u201318, https:\/\/doi.org\/10.1111\/1469-0691.12038 (2012).","journal-title":"Clin Microbiol Infect"},{"key":"53093_CR8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas, P. G. et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 62, e1\u201350, https:\/\/doi.org\/10.1093\/cid\/civ933 (2016).","journal-title":"Clin Infect Dis"},{"key":"53093_CR9","unstructured":"U.S. Food and Drug Administration. Mycamine (micafungin sodium) for injection. Product label U.S. Food and Drug Administration. Available at, http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/021506s009lbl.pdf (2007)."},{"key":"53093_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/myc.12170","volume":"57","author":"MC Arendrup","year":"2014","unstructured":"Arendrup, M. C., Cuenca-Estrella, M., Lass-Florl, C. & Hope, W. W. & European Committee on Antimicrobial Susceptibility Testing - Subcommittee on Antifungal Susceptibility, T. EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole. Mycoses 57, 377\u2013379, https:\/\/doi.org\/10.1111\/myc.12170 (2014).","journal-title":"Mycoses"},{"key":"53093_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40262-017-0578-5","volume":"57","author":"RE Wasmann","year":"2018","unstructured":"Wasmann, R. E. et al. Clinical Pharmacokinetics and Pharmacodynamics of Micafungin. Clin Pharmacokinet 57, 267\u2013286, https:\/\/doi.org\/10.1007\/s40262-017-0578-5 (2018).","journal-title":"Clin Pharmacokinet"},{"key":"53093_CR12","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1177\/0091270005279580","volume":"45","author":"MF Hebert","year":"2005","unstructured":"Hebert, M. F. et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 45, 1145\u20131152, https:\/\/doi.org\/10.1177\/0091270005279580 (2005).","journal-title":"J Clin Pharmacol"},{"key":"53093_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13318-014-0204-y","volume":"40","author":"N Undre","year":"2015","unstructured":"Undre, N., Pretorius, B. & Stevenson, P. Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction. Eur J Drug Metab Pharmacokinet 40, 285\u2013293, https:\/\/doi.org\/10.1007\/s13318-014-0204-y (2015).","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"53093_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.diagmicrobio.2007.09.018","volume":"60","author":"T Gumbo","year":"2008","unstructured":"Gumbo, T. et al. Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis 60, 329\u2013331, https:\/\/doi.org\/10.1016\/j.diagmicrobio.2007.09.018 (2008).","journal-title":"Diagn Microbiol Infect Dis"},{"key":"53093_CR15","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1128\/AAC.05193-11","volume":"55","author":"RG Hall","year":"2011","unstructured":"Hall, R. G., Swancutt, M. A. & Gumbo, T. Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrob Agents Chemother 55, 5107\u20135112, https:\/\/doi.org\/10.1128\/AAC.05193-11 (2011).","journal-title":"Antimicrob Agents Chemother"},{"key":"53093_CR16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts, J. A. et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14, 498\u2013509, https:\/\/doi.org\/10.1016\/S1473-3099(14)70036-2 (2014).","journal-title":"Lancet Infect Dis"},{"key":"53093_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/jac\/dkw352","volume":"72","author":"V Jullien","year":"2017","unstructured":"Jullien, V. et al. Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation. J Antimicrob Chemother 72, 181\u2013189, https:\/\/doi.org\/10.1093\/jac\/dkw352 (2017).","journal-title":"J Antimicrob Chemother"},{"key":"53093_CR18","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1128\/AAC.00623-15","volume":"59","author":"VJ Lempers","year":"2015","unstructured":"Lempers, V. J. et al. Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients. Antimicrob Agents Chemother 59, 4403\u20134409, https:\/\/doi.org\/10.1128\/AAC.00623-15 (2015).","journal-title":"Antimicrob Agents Chemother"},{"key":"53093_CR19","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s40262-017-0509-5","volume":"56","author":"LC Martial","year":"2017","unstructured":"Martial, L. C. et al. Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients. Clin Pharmacokinet 56, 1197\u20131206, https:\/\/doi.org\/10.1007\/s40262-017-0509-5 (2017).","journal-title":"Clin Pharmacokinet"},{"key":"53093_CR20","doi-asserted-by":"publisher","unstructured":"Vossen, M. G. et al. Micafungin Plasma Levels Are Not Affected by Continuous Renal Replacement Therapy: Experience in Critically Ill Patients. Antimicrob Agents Chemother 61, https:\/\/doi.org\/10.1128\/AAC.02425-16 (2017).","DOI":"10.1128\/AAC.02425-16"},{"key":"53093_CR21","doi-asserted-by":"publisher","unstructured":"Boonstra, J. M. et al. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis. Antimicrob Agents Chemother 61, https:\/\/doi.org\/10.1128\/AAC.01398-17 (2017).","DOI":"10.1128\/AAC.01398-17"},{"key":"53093_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2019-8","volume":"22","author":"E Maseda","year":"2018","unstructured":"Maseda, E. et al. Population pharmacokinetics\/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients. Crit Care 22, 94, https:\/\/doi.org\/10.1186\/s13054-018-2019-8 (2018).","journal-title":"Crit Care"},{"key":"53093_CR23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.ijantimicag.2016.02.004","volume":"47","author":"Q Yang","year":"2016","unstructured":"Yang, Q. et al. Pharmacokinetic\/pharmacodynamic adequacy of echinocandins against Candida spp. in intensive care unit patients and general patient populations. Int J Antimicrob Agents 47, 397\u2013402, https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.02.004 (2016).","journal-title":"Int J Antimicrob Agents"},{"key":"53093_CR24","unstructured":"European Medicines Agency. Guideline on Bioanalytical Method Validation. Available at, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109686.pdf (2011)."},{"key":"53093_CR25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom, L., Pihlgren, P. & Jonsson, E. N. PsN-Toolkit\u2013a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79, 241\u2013257, https:\/\/doi.org\/10.1016\/j.cmpb.2005.04.005 (2005).","journal-title":"Comput Methods Programs Biomed"},{"key":"53093_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson, E. N. & Karlsson, M. O. Xpose\u2013an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58, 51\u201364 (1999).","journal-title":"Comput Methods Programs Biomed"},{"key":"53093_CR27","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1038\/psp.2013.26","volume":"2","author":"W Byon","year":"2013","unstructured":"Byon, W. et al. Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst Pharmacol 2, e51, https:\/\/doi.org\/10.1038\/psp.2013.26 (2013).","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"53093_CR28","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould, D. R. & Upton, R. N. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 2, e38, https:\/\/doi.org\/10.1038\/psp.2013.14 (2013).","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"53093_CR29","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1023\/a:1011970125687","volume":"15","author":"EN Jonsson","year":"1998","unstructured":"Jonsson, E. N. & Karlsson, M. O. Automated covariate model building within NONMEM. Pharm Res 15, 1463\u20131468, https:\/\/doi.org\/10.1023\/a:1011970125687 (1998).","journal-title":"Pharm Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53093-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53093-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53093-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T11:32:26Z","timestamp":1671276746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53093-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["53093"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-53093-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"4 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was supported with a research grant by Astellas Pharma to B.E. The funding source was not involved in the conception of the study, data collection, data analysis, decision to publish or the writing of the manuscript. C.L., D.H. and B.E. have received honoraria by Astellas Pharma for speaking at symposia. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17741"}}